Gossamer Bio Inc (GOSS)

Currency in USD
1.920
-0.070(-3.52%)
Closed·
1.9200.000(0.00%)
·
GOSS Scorecard
Full Analysis
Quickly burning through cash
GOSS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.9102.000
52 wk Range
0.6622.230
Key Statistics
Prev. Close
1.92
Open
1.97
Day's Range
1.91-2
52 wk Range
0.662-2.23
Volume
1.19M
Average Volume (3m)
2.56M
1-Year Change
105.72%
Book Value / Share
-0.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GOSS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.750
Upside
+303.65%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Gossamer Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Gossamer Bio Inc Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $9.9M exceeded $4.25M forecast; EPS loss of $0.16 beat expected $0.19 loss
  • Stock rose 3.96% post-earnings; company maintains 'GOOD' financial health score per InvestingPro
  • Strong cash position of $257.9M; focus on pulmonary hypertension treatments
  • Top-line results from PROCERA Phase 3 study expected Feb 2026; SERENADA Phase 3 to start Q4 2025
  • Analysts forecast 83% revenue decline for FY2025 despite Q1 outperformance
Last Updated: 15/05/2025, 22:48
Read Full Transcript

Compare GOSS to Peers and Sector

Metrics to compare
GOSS
Peers
Sector
Relationship
P/E Ratio
−3.1x−1.2x−0.6x
PEG Ratio
0.05−0.050.00
Price/Book
−9.5x1.7x2.6x
Price / LTM Sales
10.8x7.8x3.3x
Upside (Analyst Target)
309.2%305.7%40.1%
Fair Value Upside
Unlock26.8%5.3%Unlock

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.750
(+303.65% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.17 / -0.1805
Revenue / Forecast
11.49M / 4.12M
EPS Revisions
Last 90 days

GOSS Income Statement

People Also Watch

235.18
AVAV
-4.84%
5.500
BBAI
-5.98%
29.33
CNC
+1.17%
69.29
MP
-4.04%
3.590
ONDS
-10.47%

FAQ

What Stock Exchange Does Gossamer Bio Trade On?

Gossamer Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Gossamer Bio?

The stock symbol for Gossamer Bio is "GOSS."

What Is the Gossamer Bio Market Cap?

As of today, Gossamer Bio market cap is 435.43M.

What Is Gossamer Bio's Earnings Per Share (TTM)?

The Gossamer Bio EPS (TTM) is -0.61.

When Is the Next Gossamer Bio Earnings Date?

Gossamer Bio will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is GOSS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Gossamer Bio Stock Split?

Gossamer Bio has split 0 times.

How Many Employees Does Gossamer Bio Have?

Gossamer Bio has 145 employees.

What is the current trading status of Gossamer Bio (GOSS)?

As of 20 Aug 2025, Gossamer Bio (GOSS) is trading at a price of 1.92, with a previous close of 1.92. The stock has fluctuated within a day range of 1.91 to 2.00, while its 52-week range spans from 0.66 to 2.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.